Table 2.
Univariate and multivariate analyses of progression‐free and overall survival
| Characteristic | Subgroups | HR for PFS (95% CI) | HR for OS (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate | P‐value | Multivariate | P‐value | Univariate | P‐value | Multivariate | P‐value | ||
| Age | <65 years/≥65 years | 1.16 (0.84–1.58) | 0.33 | 0.86 (0.58–1.23) | 0.41 | ||||
| Sex | Male/Female | 1.15 (0.85–1.54) | 0.33 | 1.42 (1.00–1.99) | 0.04 | 1.08 (0.71–1.64) | 0.68 | ||
| Smoking status | Ever/never | 1.12 (0.82–1.51) | 0.44 | 1.53 (1.08–2.15) | 0.01 | 1.59 (1.04–2.43) | 0.03 | ||
| ECOG‐PS | 2–4/0–1 | 2.82 (1.96–3.98) | <0.01 | 2.22 (1.48–3.28) | <0.01 | 4.12 (2.75–6.07) | <0.01 | 3.46 (2.15–5.47) | <0.01 |
| Line of EGFR‐TKI | 1/≥2 | 0.97 (0.70–1.36) | 0.87 | 0.94 (0.65–1.39) | 0.76 | ||||
| EGFR‐TKI | Gefitinib or erlotinib/afatinib | 1.75 (1.17–2.74) | <0.01 | 1.55 (1.03–2.43) | 0.03 | 1.75 (1.04–3.20) | 0.03 | 1.39 (0.81–2.57) | 0.23 |
| EGFR mutation | Ex19del or L858R/other | 0.55 (0.30–1.17) | 0.11 | 0.46 (0.23–1.11) | 0.08 | ||||
| T790M mutation | Yes/No or unknown | 0.86 (0.50–1.38) | 0.56 | 0.42 (0.19–0.81) | <0.01 | 0.54 (0.24–1.06) | 0.07 | ||
| GPS score | 2/0–1 | 2.44 (1.58–3.63) | <0.01 | 1.66 (1.03–2.61) | 0.03 | 3.59 (2.22–5.60) | <0.01 | 1.77 (1.03–2.97) | 0.03 |
CI, confidence interval; ECOG‐PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; GPS, Glasgow prognostic score; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor.